contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


invitation-to-presentation-of-acarixs-first-quarter-report

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Acarix is a diagnostics company. The company has developed a technology that enables the identification of coronary artery disease. The company's product is a non-invasive test that is applied with a patch to the patient to analyze sounds from the heart. The business is conducted primarily within the Nordic market. The company was founded in 2009 as a spin-off from Coloplast. The headquarters are located in Malmö.

Acarix

Acarix will publish its first quarter results on Thursday 11 May 2023 at 08.00 am (CEST). A live webcast will be held at 14.00 (CEST) the same day, where CEO Helen Ljungdahl Round and CFO Christian...

<div class="mfn-preamble"><p><strong>Acarix will publish its first quarter results on Thursday 11 May 2023 at 08.00 am (CEST). A live webcast will be held at 14.00 (CEST) the same day, where CEO Helen Ljungdahl Round and CFO Christian Lindholm will present the report. The presentation ends with a Q&amp;A together with Redeye's analysts, where you can ask the company questions via the form on the live page.</strong></p></div><div class="mfn-body"><p>The webcast will be available at <a rel="noopener" href="https://www.redeye.se/events/895520/live-q-acarix-4">https://www.redeye.se/events/895520/live-q-acarix-4</a><br>The presentation will be available at <a rel="noopener" href="https://www.acarix.com/for-investors/investor-presentations">https://www.acarix.com/for-investors/investor-presentations</a>&nbsp;<br>after the webcast.</p></div><div class="mfn-footer mfn-contacts mfn-5f6793025012"><p><strong class="mfn-heading-1">For more information contact:</strong><br>Helen Ljungdahl Round, CEO, phone +1 267 809 1225, +46&nbsp;730 770283, email <a rel="noopener" href="mailto:helen.round@acarix.com">helen.round@acarix.com</a>&nbsp;<br>Christian Lindholm, CFO, phone +46&nbsp;705 118333, email <a rel="noopener" href="mailto:christian.lindholm@acarix.com">christian.lindholm@acarix.com</a></p></div><div class="mfn-footer mfn-about mfn-ddf9d1ef3849"><p><strong class="mfn-heading-1">About Acarix</strong></p><table><tbody><tr><td rowspan="1" colspan="1">Acarix is a Swedish medical device company that innovates solutions for rapid AI-based rule out of Coronary Artery Disease (CAD). The CE approved and FDA DeNovo cleared Acarix CADScor®System is intended for patients experiencing chest pain with suspected CAD and designed to help reduce millions of unnecessary, invasive and costly diagnostic procedures. The CADScor System uses advanced acoustics and AI-technology to rule out CAD non-invasively in less than 10 minutes, with at least 96% certainty. Acarix is listed on the Nasdaq First North Premier Growth Market in Stockholm (ticker: ACARIX). Redeye AB (+46 (0)8 121 576 90, <a rel="noopener" href="mailto:certifiedadviser@redeye.se">certifiedadviser@redeye.se</a>) is Certified Advisor of Acarix. For more information, please visit <a rel="noopener" href="http://www.acarix.com">www.acarix.com</a>.&nbsp;</td></tr></tbody></table></div><div class="mfn-footer mfn-attachment mfn-attachment-general"><p><strong class="mfn-heading-1">Attachments</strong><br><a rel="noopener" href="https://storage.mfn.se/0ba2d0e9-1111-42da-ad85-740406da92b2/invitation-to-presentation-of-acarix-s-first-quarter-report.pdf" class="mfn-generated mfn-primary">Invitation to presentation of Acarix´s first quarter report</a></p></div>